News about "GSK"

Jideytro Wins US Approval for ROS1-Positive NSCLC

Jideytro (zidesamtinib) has won US approval for previously treated ROS1-positive NSCLC, backed by ARROS-1 trial results showing durable responses.

GSK | 24/07/2026 | By News Bureau |  107

EMA Accepts Bexsero Label Update for Meningitis B Booster

The European Medicines Agency (EMA) has accepted a label update for Bexsero that could enable a single booster dose to protect individuals aged 10 years and older previously vaccinated against Meningitis B.

GSK | 21/07/2026 | By News Bureau |  103

GSK's Jemperli Shows Durable Complete Responses in Rectal CancerGSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally adva

GSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally advanced rectal cancer, with potential to avoid chemotherapy, radiation, and surgery in some patients.

GSK | 14/07/2026 | By News Bureau

US FDA Approves Utebzi for Adult Patients with Complicated UTIs

The US Food and Drug Administration (FDA) has approved GSK’s Utebzi (tebipenem pivoxil) for adults with complicated Urinary Tract Infections (cUTIs), becoming the first and only oral carbapenem antibiotic available. The approval is based on the phase 3 PIVOT-PO trial, which demonstrated non-inferiority to standard intravenous antibiotic treatment.

GSK | 19/06/2026 | By News Bureau |  130

GSK Enters Agreement to Acquire Nuvalent

GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.

GSK | 10/06/2026 | By News Bureau |  254

GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment

GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.

GSK | 29/05/2026 | By News Bureau |  229

GSK Partners with Sino Biopharmaceutical to Accelerate Hepatitis B Therapy Launch in China

GSK and Sino Biopharmaceutical’s CTTQ have partnered to accelerate the launch of bepirovirsen in China, aiming to expand access to a potential first-in-class chronic hepatitis B therapy with functional cure potential.

GSK | 12/05/2026 | By News Bureau |  129

Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research

Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.

GSK | 07/05/2026 | By News Bureau |  126

GSK Acquires 100 Percent Equity of 35Pharma for USD 950 Million

GSK completes acquisition of 35Pharma, adding HS235, a potential best-in-class therapy for Pulmonary Hypertension.

GSK | 16/04/2026 | By News Bureau |  118

GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers

GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.

GSK | 14/04/2026 | By News Bureau |  187